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Abstract
The Disease Control Priorities (DCP) project has substantially influenced national and global health priorities 
since 1993. DCP’s basic framework involves identification of disease burdens based on premature deaths and 
disability and application of the most cost-effective interventions to the largest burdens, taking into account 
local feasibility. The future impact of DCP will need to take into account growing national wealth and needs 
for endogenous capacity to design and implement evidence-based interventions, the rapid emergence of 
non-communicable disease (NCD), and the universal health coverage (UHC) agenda. This in turn requires 
three improvements to the DCP framework: greater local capacity, supported by a global effort to cost health 
interventions, stronger national and international technical capacity and networks, and the use of direct, versus 
modelled, mortality data to assign priorities and to assess progress. Properly done, DCP could be as important 
over the next 25 years as it has been in the past 25 years.
Keywords: Priority Setting in Health, Economic Evaluation, Global Burden of Disease, Direct Mortality 
Measurement
Copyright: © 2019 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Citation: Jha P. The future of disease control priorities: Comment on “Disease control priorities third edition 






Received: 16 October 2018
Accepted: 28 November 2018
ePublished: 10 December 2018
Commentary
Centre for Global Health Research, St. Michael’s Hospital and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
http://ijhpm.com
Int J Health Policy Manag 2019, 8(3), 177–180 doi 10.15171/ijhpm.2018.119
The Future of Disease Control Priorities 
For much of the last 25 years, the framework set out in the 
Disease Control Priorities (DCP) project has influenced 
global health directions. The basic framework is to identify 
disease burdens based on premature deaths and disability, 
and then apply the most cost-effective interventions to the 
largest burdens, taking into account local feasibility. These 
are assembled into priority “packages” that can be introduced 
at the country level, as illustrated from DCP application to 
India (Figure).1 DCP12 informed the World Bank’s influential 
World Development Report (WDR) Investing in Health.3 
DCP2 followed in 2006 and deepened the analyses of health 
systems.4 DCP3, published during 2014-2017, expanded the 
methodology to focus on poverty reduction and to ensure 
recommended packages aligned with the World Health 
Organization’s (WHO’s) plans for universal health coverage 
(UHC).5 DCP3 is thus particularly relevant to various disease- 
and poverty-specific sub-goals within the United Nations 
Sustainable Development Goals.6
DCP’s influence, as reviewed by Ole Norheim,7 has been 
wide and deep on country applications and global health 
priority setting. Norheim lays out a Theory of Change that 
would increase the use of DCP methods at the country level. 
To supplement his useful ideas, I comment on the impact 
of DCP and the complementary role of reliable and direct 
measures of disease burden. I provide three directions for 
better use of evidence at the global and at the country level.
Impact of Disease Control Priorities
DCP1 informed the design of a $1 billion portfolio of World 
Bank-assisted state-level health systems and categorical 
disease control programs in India.8 More recently, the DCP2 
methodology has been applied nationally1 and for the state 
of Karnataka,9 and is influencing the debate on introduction 
of UHC. Similarly, DCP1 influenced the design of Mexico’s 
healthcare reforms.10 Norheim and Dean Jamison, the lead 
author of the WDR and chief editor of DCP, both point out 
the more limited uptake of DCP in other low- and middle-
income countries (LMICs). The main constraint is inadequate 
technical capacity in many LMICs to generate and use the 
DCP methodology.5,7 Less equivocally, DCP1 motivated Bill 
and Melinda Gates to invest in global health through the Bill 
& Melinda Gates Foundation.11 DCP1, paired later with the 
Commission on Macroeconomics and Health, played a role in 
catalysing the Global Fund to Fight AIDS, Tuberculosis and 
Malaria.12
Quantifying the impact of DCP1 and DCP2 is difficult, 
given problems attributing impact to disease control programs 
recommended by DCP. An interesting, albeit limited, 
comparison is of the equal value for money of a $50 million 
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investment on HIV control in India by the Government 
of India and the World Bank (beginning in 1999) when 
compared to the Gates Foundation’s Avahan, which spent 
about 5 times more (and began later). India’s Second National 
HIV/AIDS Program drew broadly on DCP1 work led by Peter 
Piot and others2 that recommended prevention and treatment 
of sexually-transmitted infection in female sex workers as 
being particularly cost-effective. A quantitative analysis 
showed that each additional sexually-transmitted infection 
treated in India appeared to reduce the risk of HIV or syphilis 
infection in pregnant women from 2003-2008 (as a surrogate 
of HIV infection in the general population). Importantly, 
there was no difference between the cheaper Government of 
India-funded and more expensive Avahan-funded programs 
in the reductions in HIV or syphilis.13
Figure. Design of Priority Intervention (“Entitlement”) Packages in India to 
Tackle Major Causes of Premature Mortality.1
Table. Differences Between GBD Rankings of India’s DALYs Lost (a 
Combined Measure of Premature Mortality and Serious Disability) for 
2010 and 2015
Indian DALYs: 2010 Ranking Indian DALYs: 2015 Ranking
1 Diet 1 Blood pressure
2 Household air pollution 2 Fasting plasma glucose
3 Smoking 3 Ambient particulates
4 Blood pressure 4 Household air pollution
5 Childhood underweight 5 Unsafe water
6 Occupational risks 6 Childhood undernutrition
7 Ambient particulates 7 Smoking
8 Fasting plasma glucose 8 Total cholesterol
9 Iron deficiency 9 Iron deficiency
10 Alcohol 10 Diet lacking whole grains
Abbreviations: GBD, Global Burden of Disease; DALYs, disability-adjusted life 
years.
These temporal changes in rankings are mostly due to changes in model 
assumptions, not in the risk factors themselves.
Source: author calculations based on GBD.14
Reliable Mortality Burdens
An early innovation in the DCP methodology was to estimate 
disease burdens alongside economic analyses. Jamison 
conceived the idea of the Global Burden of Disease (GBD) 
in the early 1990s, drawing upon Alan Lopez’s assembly of 
consistent estimates of death by cause worldwide, the Richard 
Zeckhauser and Don Shepard metric that combined fatal and 
non-fatal health events (which led to the disability-adjusted 
life year, or DALY), and Howard Barnum’s illustration of 
national burden of disease in Ghana that combined non-
fatal outcomes with consistent cause of death estimates. 
Jamison contracted Harvard University to make calculations 
for WDR, which resulted in the first (1990) GBD estimate.12 
Lopez and Chris Murray have subsequently expanded the 
GBD markedly.14
At the global level, the 1990 (and 2000) GBD was an 
important advance, mostly in ensuring consistent estimates 
of the causes of death for the world and for major regions.4,12 
However, subsequent estimates for the national level have 
been problematic.15 This is because the evidence on causes of 
death, and to a lesser extent on levels of mortality, in the GBD 
are based far more on econometric models than on actual data 
(and indeed often on models of models). Not surprisingly, 
this leads to odd results. For example, the modelled data 
stated that child mortality was rising by 3% a year in South 
Africa, whereas direct data from local census and statistical 
agencies found that it was falling at 3% a year.16 The estimation 
of the burden of causal risk factors (which is particularly 
needed for control of non-communicable diseases [NCDs]) 
is also challenging. India’s ranking of causal risk factors was 
markedly different between 2010 and 2015 (Table).14
The Way Forward
DCP3’s impact will materialize over the next few years. Three 
major factors are likely to influence uptake of DCP evidence: 
the growing wealth of many LMICs, the emergence of NCDs 
as the main challenge facing many countries, and the priority 
laid out by WHO to advance UHC and the related World Bank 
agenda to improve human capital (which includes both child 
and adult mortality, along with nutrition and educational 
achievement).17
Rising wealth means that many LMICs can now implement 
interventions that they would not have considered earlier. 
Naturally, expectations are clear that Ministries of Health, and 
not donors or Western universities, should drive the evidence 
agenda. The emergence of NCDs implies that far more 
reliable country-level quantification of risk factors is required 
than that produced by the currently unreliable models, paired 
with strategies to scale up NCD prevention and treatment. 
The obvious priorities are large increases in tobacco taxation 
and other tobacco control efforts, combined with access to 
low-cost treatment of curable or treatable common vascular 
conditions and cancers.5,12,18 At the national level, DCP can 
help design intervention packages for UHC. For example, the 
Ayushman Bharat program in India, which aims to expand 
health insurance to 500 million Indians, has broadly adopted 
Jha
International Journal of Health Policy and Management, 2019, 8(3), 177–180 179
cost-effectiveness and use of treatment packages.19
Three changes in the DCP approach are required to meet the 
changing landscape of global health, and to ensure relevance 
to countries. First, a substantial investment is needed to build 
on the DCP3 work, in particular in costing various health 
interventions (individual or combined) in different settings 
with markedly dissimilar cost structures. In particular, these 
will need to pay attention to the community and population-
based strategies to tackle the risk factors which are emerging 
from epidemiological studies in LMICs (such as the unique 
role of low body weight in explaining the high risks of vascular 
disease in India).20,21 These data should be shared openly and 
publically for unrestricted use on a globally accessible website. 
A large costing platform, building upon the WHO’s earlier 
“CHOICE” analyses would substantially reduce one of the 
lingering uncertainties in the design of intervention packages.5 
Second, as Norheim argues,7 much stronger technical capacity 
is needed, including creation of national public or voluntary 
institutions to do rational planning and analyses free from 
the vagaries of daily fire-fighting that is all too common for 
most ministries of health. Such efforts are commensurate 
with building national country capacity for governance and 
monitoring. Global networks of DCP practitioners, akin to 
successful clinical epidemiological networks, are needed to 
increase use and uptake in many LMICs. A DCP network 
would be a good investment.
Third, the design of DCP intervention packages and the 
monitoring of their impact require far more reliance on 
direct mortality data than on models. Direct mortality data 
are needed to assess the impact of programs as modelled 
data cannot separate real changes from changing modelling 
assumptions. Mortality remains central to burden measures as 
it comprises most premature deaths and disability in LMICs, 
and can be measured reliably at low-cost.15,22 Disability 
measurement is less certain, and has far more measurement 
error than vital status and causes of death. 
A practicable solution is to build large, simple nationwide 
mortality systems that capture a random sample of all deaths, 
such as the Registrar General of India’s Million Death Study 
(MDS).22 The MDS yielded major findings that substantially 
changed previous estimates of mortality and the relevance 
of particular risk factors. For example, it showed that India 
had only about 0.1 million premature HIV deaths in 2005, 
about a quarter of the total estimated by WHO models, but 
that India had far more deaths from malaria than the WHO 
had estimated. The MDS was able to directly document that 
a Government of India program has helped reduce child 
deaths by about 1 million over the past decade, including a 
90% reduction in measles mortality.23 The Gates Foundation 
and the Canadian government are investing in nationwide 
mortality surveillance in African countries. However, further 
expansion is required. A “25 by 25” goal is desirable. This 
would aim for 25 major LMICs to have reliable, nationally 
representative cause of death reporting by 2025.
Dean Jamison’s extraordinary vision of DCP and the 
GBD has transformed global health. With further practical 
improvements, the relevance of DCP evidence generation and 
application over the next 25 years could be as important as in 
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